Programmed death ligand-1 expression in non-small cell lung cancer

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival

(2013) E. J. Lipson et al.   Cancer Immunology Research

Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung

(2012) Jennifer M. Boland et al.   Clinical Lung Cancer

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen

(2012) Jennifer M. Bordeaux et al.   PLoS One

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

The New Lung Cancer Staging System

(2009) Frank C. Detterbeck et al.   CHEST

Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

(2009) Nicholas J. Petrelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung Adenocarcinoma

(2008) Valsamo K. Anagnostou et al.   JOURNAL OF CLINICAL ONCOLOGY